Literature DB >> 1281625

Morphine and hydromorphone epidural analgesia. A prospective, randomized comparison.

S R Chaplan1, S R Duncan, J B Brodsky, W G Brose.   

Abstract

Because evidence from uncontrolled, unblinded studies suggested fewer side effects from epidural hydromorphone than from epidural morphine, we employed a randomized, blinded study design to compare the side effects of lumbar epidural morphine and hydromorphone in 55 adult, non-obstetric patients undergoing major surgical procedures. A bolus dose of epidural study drug was given at least 1 h prior to the conclusion of surgery, followed by a continuous infusion of the same drug for two postoperative days. Infusions were titrated to patient comfort. Visual analog scale (VAS) pain scores, VAS sedation scores, and subjective ratings of nausea and pruritus were assessed twice daily. The two treatments provided equivalent analgesia. Sedation scores and prevalence of nausea did not differ significantly between groups. Prevalence of pruritus, however, differed significantly on postoperative day 1, with moderate to severe pruritus reported by 44.4% of patients in the morphine group versus 11.5% in the hydromorphone group (P < .01). On post-operative day 2, reports of pruritus by patients receiving morphine remained higher than those among the hydromorphone-treated subjects, although this difference was no longer statistically significant (32% vs. 16.7%, P = .18). We conclude that lumbar epidural morphine and hydromorphone afford comparable analgesia, but the occurrence of moderate to severe pruritus on the first postoperative day is reduced by the use of hydromorphone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281625     DOI: 10.1097/00000542-199212000-00008

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  Comparison of Morphine- and Hydromorphone-Containing Patient-Controlled Epidural Analgesia Solutions in Pediatric Postoperative Patients.

Authors:  Jesse Cramer
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Jan-Feb

2.  Epidural morphine vs hydromorphone in post-caesarean section patients.

Authors:  S H Halpern; R Arellano; R Preston; J Carstoniu; G O'Leary; S Roger; A Sandler
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

3.  Intra-articular Analgesia and Discharge to Home Enhance Recovery Following Total Knee Replacement.

Authors:  Shivi Duggal; Susan Flics; Charles N Cornell
Journal:  HSS J       Date:  2014-11-12

4.  Intrathecal Morphine versus Intrathecal Hydromorphone for Analgesia after Cesarean Delivery: A Randomized Clinical Trial.

Authors:  Emily E Sharpe; Rochelle J Molitor; Katherine W Arendt; Vanessa E Torbenson; David A Olsen; Rebecca L Johnson; Darrell R Schroeder; Adam K Jacob; Adam D Niesen; Hans P Sviggum
Journal:  Anesthesiology       Date:  2020-06       Impact factor: 7.892

5.  Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.

Authors:  Cheol Kyu Park; Hyun Wook Kang; In Jae Oh; Young Chul Kim; Yeo Kyeoung Kim; Kook Joo Na; Sung Ja Ahn; Tae Ok Kim; Young Jin Choi; Geun Am Song; Min Ki Lee
Journal:  J Korean Med Sci       Date:  2016-12       Impact factor: 2.153

Review 6.  The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain.

Authors:  J E Pope; T R Deer; K Amirdelfan; W P McRoberts; N Azeem
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  Continuous Epidural Hydromorphone Infusion for Post-Cesarean Delivery Analgesia in a Patient on Methadone Maintenance Therapy: A Case Report.

Authors:  Mellany A Stanislaus; Joseph L Reno; Robert H Small; Julie H Coffman; Mona Prasad; Avery M Meyer; Kristen M Carpenter; John C Coffman
Journal:  J Pain Res       Date:  2020-04-28       Impact factor: 3.133

Review 8.  The Options for Neuraxial Drug Administration.

Authors:  Henning Hermanns; Elke M E Bos; Mark L van Zuylen; Markus W Hollmann; Markus F Stevens
Journal:  CNS Drugs       Date:  2022-07-15       Impact factor: 6.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.